Clinical data | |
---|---|
Trade names | Drolban, Masteril, Masteron, others (all as drostanolone propionate) |
Other names | Dromostanolone; 2α-Methyl-4,5α-dihydrotestosterone; 2α-Methyl-DHT; 2α-Methyl-5α-androstan-17β-ol-3-one |
Routes of administration | Intramuscular injection (as drostanolone propionate) |
Drug class | Androgen; Anabolic steroid |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.334 |
Chemical and physical data | |
Formula | C20H32O2 |
Molar mass | 304.474 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Drostanolone, or dromostanolone, is an anabolic–androgenic steroid (AAS) of the dihydrotestosterone (DHT) group which was never marketed.[2][3][4] An androgen ester prodrug of drostanolone, drostanolone propionate, was formerly used in the treatment of breast cancer in women under brand names such as Drolban, Masteril, and Masteron.[2][3][4][5] This has also been used non-medically for physique- or performance-enhancing purposes.[4]
Pharmacology
Pharmacodynamics
Medication | Ratioa |
---|---|
Testosterone | ~1:1 |
Androstanolone (DHT) | ~1:1 |
Methyltestosterone | ~1:1 |
Methandriol | ~1:1 |
Fluoxymesterone | 1:1–1:15 |
Metandienone | 1:1–1:8 |
Drostanolone | 1:3–1:4 |
Metenolone | 1:2–1:30 |
Oxymetholone | 1:2–1:9 |
Oxandrolone | 1:3–1:13 |
Stanozolol | 1:1–1:30 |
Nandrolone | 1:3–1:16 |
Ethylestrenol | 1:2–1:19 |
Norethandrolone | 1:1–1:20 |
Notes: In rodents. Footnotes: a = Ratio of androgenic to anabolic activity. Sources: See template. |
Like other AAS, drostanolone is an agonist of the androgen receptor (AR).[4] It is not a substrate for 5α-reductase and is a poor substrate for 3α-hydroxysteroid dehydrogenase (3α-HSD), and therefore shows a high ratio of anabolic to androgenic activity.[4] As a DHT derivative, drostanolone is not a substrate for aromatase and hence cannot be aromatized into estrogenic metabolites.[4] While no data are available on the progestogenic activity of drostanolone, it is thought to have low or no such activity similarly to other DHT derivatives.[4] Since the drug is not 17α-alkylated, it is not known to cause hepatotoxicity.[4]
Chemistry
Drostanolone, also known as 2α-methyl-5α-dihydrotestosterone (2α-methyl-DHT) or as 2α-methyl-5α-androstan-17β-ol-3-one, is a synthetic androstane steroid and a derivative of DHT.[2][3][4] It is specifically DHT with a methyl group at the C2α position.[2][3][4]
History
Drostanolone and its ester drostanolone propionate were first described in 1959.[4][6] Drostanolone propionate was first introduced for medical use in 1961.[7]
Society and culture
Generic names
Drostanolone is the generic name of the drug and its INN , BAN , and DCF .[2][3] It has also been referred to as dromostanolone.[2][3]
Legal status
Drostanolone, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act.[8]
Synthesis
Bolazine is when react 2 eq. with hydrazine to give dimer
Treatment of DHT (androstan-17β-ol-3-one, stanolone) [521-18-6] (1) with methyl formate and the strong base sodium methoxide gives [4033-95-8] (2). The newly added formyl function in the product is shown in the enol form. Catalytic hydrogenation reduces that function to a methyl group (3). The addition of hydrogen from the bottom face of the molecule leads to the formation of β-methyl isomer where the methyl group occupies the higher-energy axial position. Strong base-induced equilibration of the methyl group leads to the formation of the sterically favoured equatorial α-methyl isomer, affording dromostanolone (4).
References
- ↑ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-15.
- 1 2 3 4 5 6 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 652–. ISBN 978-1-4757-2085-3.
- 1 2 3 4 5 6 Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 377–. ISBN 978-3-88763-075-1.
- 1 2 3 4 5 6 7 8 9 10 11 Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. pp. 517–. ISBN 978-0-9828280-1-4.
- ↑ Bennett MB, Helman P, Palmer P (November 1975). "Hormonal therapy of breast cancer with special reference to Masteril therapy". South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde. 49 (49): 2036–40. PMID 1242823.
- ↑ Ringold HJ, Batres E, Halpern O, Necoechea E (1959). "Steroids. CV.12-Methyl and 2-Hydroxymethylene-androstane Derivatives". Journal of the American Chemical Society. 81 (2): 427–432. doi:10.1021/ja01511a040. ISSN 0002-7863.
- ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 1402–. ISBN 978-0-8155-1856-3.
- ↑ Karch SB (21 December 2006). Drug Abuse Handbook, Second Edition. CRC Press. pp. 30–. ISBN 978-1-4200-0346-8.
- ↑ Ringold HJ, Batres E, Halpern O, Necoechea E (January 1959). "Steroids. CV. 1 2-Methyl and 2-hydroxymethylene-androstane derivatives". Journal of the American Chemical Society. 81 (2): 427–432. doi:10.1021/ja01511a040.
- ↑ Volovel'skii, L.N. et al, Zh. Obschch. Khim., 1966, 46, 1772.
- ↑ US 2908693, Ringold HJ, Rosenkranz G, issued 1959, assigned to Syntex SA
- ↑ US 3118915, Ringold HJ, Rosenkranz G, issued 1964, assigned to Roche Palo Alto LLC
- ↑ GB 1005896 US 3249627, issued 1966, assigned to Ormonoterapia Richter Spa